Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Michael Brody who wrote (883)	5/27/1999 10:53:00 AM
From: New Economy	Read Replies (1) \| Respond to of 2344

Thu 27 May 99 In the News The Vancouver Sun reports in a Southam dispatch in its Thursday edition that: Biomira could get regulatory approval for its vaccine against breast cancer in as little as two years. Reporter Dan Westell notes that Biomira's Theratope vaccine against breast cancer has begun Stage 3 trials, and if it works, regulators could approve it as early as the middle to end of 2001, according to Alex McPherson, the company's president and chief executive. He says the stage is clearly set for immunotherapy, which has moved to the forefront in the fight against cancer. He says that science is on the cusp of some very important developments. Edmonton-based Biomira says it is close to marketing a viable biotechnology product. It has begun testing Theratope on 900 patients at 75 locations worldwide, including up to four in Canada. So far, 101 patients have been enlisted. Women who have had breast cancer and chemotherapy will try the drug.